about
TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancersPrognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature ReviewMolecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and diseaseMultivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancerAspirin use, tumor PIK3CA mutation, and colorectal-cancer survivalThe IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 montPhase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerEffect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancerPhase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancerPhase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance)Physical activity and male colorectal cancer survival.Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741.A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reactionImpact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803.A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases.Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis.Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies.Energetics in colorectal and prostate cancer.Exercise after cancer diagnosis: time to get moving.Dietary insulin load, dietary insulin index, and colorectal cancer.SMO expression in colorectal cancer: associations with clinical, pathological, and molecular featuresAssociation between body mass index and prognosis of colorectal cancer: a meta-analysis of prospective cohort studies.Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature reviewPhase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer.Aspirin dose and duration of use and risk of colorectal cancer in men.
P50
Q24288715-136159ED-FEB4-4CF3-A113-458BA2C3D59AQ24289005-BB21F562-2E2A-456F-8205-66C114127252Q24289344-3F4441E3-CD74-4017-AD2B-C23A3AD0518BQ24632418-B8B5E9C8-30DB-4B94-A8AB-E2775095FC30Q27851532-15533178-D45A-44EF-893F-E6910EC622F4Q27851557-C88403F0-FC8C-44AB-A411-A376CC13856CQ27851674-5E1342DD-C441-4461-97C0-68D6D8207D25Q28188848-38C9E98D-858E-407A-AEC3-321F4ACC4BFFQ28277824-08B94414-75EB-480E-996C-1082CE5FBF1EQ28681140-79B5312A-8EB1-44B9-A5D1-CAF20409DA88Q28728593-A96B198A-5C44-4CEC-93D2-AB2C3F491106Q30418160-D1C27C85-6249-4B79-9F22-A1DD7081602BQ30422372-8CE05556-0C6C-425F-A17B-090F43166108Q30422446-BC6B9A62-C337-4F47-A0AD-FF024350628AQ33375714-D2EB5B7A-9BCF-4711-8E07-6CD50B6F3963Q33382236-6C5ADC93-7BBA-4666-8C02-2499899789BCQ33384665-7050F88F-DEA8-401E-9C52-E02357D83D1AQ33402226-144BC88C-5D1B-424F-A479-A321A217DB87Q33407027-0A53A9C6-2022-460E-90E0-93D4E3955856Q33699665-34A299B2-84BE-4573-BA9B-84780C639A61Q33732199-19F9FD2A-BC89-40B3-B9A6-ACF49DADC330Q33768908-A82895DB-E0CC-4E5B-9F30-DFDC20FA229BQ33779574-9DF43156-0BCB-4282-BFD1-60DEB6163C79Q33791812-3E0B5D1B-09B1-4A7D-AE52-DB26E98C63EFQ33808550-EF6B7BE2-7E9D-4400-BE76-EA24522BDB11Q33883829-2951D0D2-0053-4DF8-A83E-6DDE18B0F1E8Q33908601-5D711C64-504C-4DD8-81C8-2E8AF43952CCQ34066685-0941EFD7-C79C-4F1B-A06D-A960434C4461Q34169734-24CAB396-EAD3-4CB8-9F24-0EB32A9ED5B6Q34217637-D7C4C68F-C4F3-4FAB-B54B-529E97B39E3FQ34234728-66AFACA8-CA35-424E-83EE-8EBF34D3617DQ34315768-00B79D4F-89FB-4E0F-8FB5-8927C2AB7BD8Q34361331-A171BA84-1EC2-466F-A316-2C6A19BC1EEAQ34422557-02440159-80ED-451F-A9FA-357FD58B645DQ34458644-0EB72A5A-D380-40AA-855A-8ABBC646163CQ34468759-B07027E8-1042-47B9-BAFE-E9C94B707F07Q34551974-BB62D7A2-A338-45D5-A29C-F78FC3941DA2Q34552576-AA247328-7A0D-482F-B565-3E45C9024D05Q34584122-2FB9AB68-2DC7-4C5B-94E7-F185397225F6Q34584944-4D27BBD0-C790-4809-AC88-A8D838EC55B7
P50
description
researcher
@en
wetenschapper
@nl
name
Jeffrey A Meyerhardt
@en
Jeffrey A Meyerhardt
@nl
type
label
Jeffrey A Meyerhardt
@en
Jeffrey A Meyerhardt
@nl
prefLabel
Jeffrey A Meyerhardt
@en
Jeffrey A Meyerhardt
@nl
P31
P496
0000-0002-1120-0898